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The PENTA Steering committee now recommends
antiretroviral therapy (ART) for all children and adoles-
cents living with HIV. Priority should be given to infants
and children under 3 years of age, to adolescents, and to
children with symptoms and/or low age-specific CD4
counts.
The 2015 PENTA guideline recommended considering
ART for all children diagnosed before their third birth-
day, with CD4 count guided thresholds for older chil-
dren [1]. Following the results of the START - Strategic
Timing of AntiRetroviral Treatment study, World Health
Organization (WHO), US and European guidelines now
recommend treatment for all HIV-infected adults and
adolescents irrespective of CD4 count. Such recommen-
dations take into account the benefits of universal treat-
ment in reducing onward transmission, including
mother-to-child transmission. WHO paediatric guidelines
recommend treatment for all children, with prioritization
of children under 5 years old and those with symptoms
or low CD4 counts.
The Children with HIV Early Antiretroviral Therapy
(CHER) study provided strong randomized controlled trial
(RCT) evidence for early treatment of all infants. RCT evi-
dence for the benefit of ART for children aged 1–
10 years with good CD4 counts is lacking. Previous
PENTA guidelines extended the recommendation for all
children under 3 years because of the potential for rapid
disease progression at higher CD4 counts [1]. Universal
treatment for all adolescents (WHO definition 10–
19 years) can now be recommended based on extrapola-
tion of adult START data and in prevention of onward
transmission to partners as this population becomes sex-
ually active. There is no equivalent to START data on
short- to medium-term benefits of early ART in younger
children, where there is no additional benefit of preven-
tion of onward transmission.
We recognize that, in the absence of RCT data, there
are potential concerns about the earlier start of lifelong
ART in children, with insufficient data on cumulative
toxicity and concerns regarding adherence because of
poor palatability and limited combination paediatric for-
mulations. However, there is increasing evidence of the
longer term benefits of early ART, including reduced
mortality in low- and middle-income countries, improved
neurodevelopmental, growth and pubertal outcomes,
improved immune reconstitution and reduced inflamma-
tion and latent reservoir cohort data also demonstrate a
reduced risk of virological failure when ART is started in
childhood compared with adolescence [2–5].
On this basis, we now also conclude that all children
should be started on ART. For children with good CD4
counts, time can be taken to address adherence and psy-
chosocial issues, but discussion on starting treatment
should be initiated soon after the diagnosis, and children
not on ART closely monitored.
While concern about the additional cost of providing
ART to all children in low- and middle-income settings
may require individual countries to analyse the financial
impact when changing national guidelines, in European
cohorts more than 90% of diagnosed children are already
on ART.
The potential benefits of ART outweigh the potential
problems for children of all ages living with HIV. The
time is now right to recommend ART for all children with
HIV infection.
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